Fujino Fernanda Maria Simões da Costa, Olandim Ana Amélia Campos Claro, Coggan Jennifer Anne, Carvalho Junior Antonio Deusany de, Bufalo Adriana de Queiroz Soares, Takeyama Eduardo Nishimiya, Sant'Ana Soraya Cristina, Barnabé Vagner Doja, Benites Nilson Roberti
Department of Medicine, George Galvão Hahnemannian Institute (IHGG), São Paulo, Brazil.
Computer Science Department, Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
Homeopathy. 2023 Feb;112(1):3-11. doi: 10.1055/s-0042-1749447. Epub 2022 Sep 1.
The manifestations of coronavirus disease 2019 (COVID-19) can result in several prognoses and lead patients to look for appropriate complementary or alternative treatment options according to their personal situation and available health care. Patients with mild symptoms or those who have not yet reached the maximum severity of their condition are those who seek outpatient care, where homeopathic treatment might be considered, given the well documented history of this medical system in several epidemics in the past.
The aim of this study was to compare the homeopathic treatment used for symptomatic cases of COVID-19 in March and April 2020 with cases treated in March and April 2021.
This is a retrospective observational study based on the analysis of the medical records of symptomatic COVID-19 patients treated on an outpatient basis with homeopathy at the Hahnemanniano George Galvão Institute in São Paulo, Brazil. We analyzed 54 cases, divided into two samples (27 cases in each year), similar in relation to age, gender and origin of the patients.
The development was distinct in the 2 years, with improvement of symptoms after 3 days of the first homeopathic prescription in 2020 whilst in 2021 the improvement occurred from the sixth day onward. The most frequently prescribed homeopathic medicine also differed in the two samples ( in 2020; in 2021), which indicates the different disease characteristics at these two moments of the epidemic.
In 2020, the symptomatology of the cases was mainly acute and the main medicine was . By comparison, in 2021 a greater interference from individuals' previous chronic miasmatic disease may explain the change in the main medicines used that year, with being the most prescribed in the cases studied.
2019冠状病毒病（COVID-19）的表现可能导致多种预后情况，并促使患者根据自身情况和可获得的医疗保健寻求合适的补充或替代治疗方案。症状较轻或病情尚未达到最严重程度的患者会寻求门诊治疗，鉴于顺势疗法在过去几次疫情中有充分的记载历史，可能会考虑采用顺势疗法治疗。
本研究的目的是比较2020年3月和4月用于COVID-19有症状病例的顺势疗法治疗与2021年3月和4月治疗的病例。
这是一项回顾性观察研究，基于对巴西圣保罗哈内曼尼亚诺·乔治·加尔瓦奥研究所门诊接受顺势疗法治疗的有症状COVID-19患者的病历分析。我们分析了54例病例，分为两个样本（每年27例），在患者年龄、性别和来源方面相似。
两年的病情发展情况不同，2020年首次服用顺势疗法药物3天后症状有所改善，而2021年从第六天开始症状改善。两个样本中最常使用的顺势疗法药物也有所不同（2020年为 ；2021年为 ），这表明疫情这两个阶段疾病特征不同。
2020年，病例症状主要为急性，主要药物为 。相比之下，2021年个体先前慢性瘴气病的更大干扰可能解释了当年所用主要药物的变化，在所研究的病例中 是最常使用的药物。
